Biora Therapeutics, Inc. (BIOR)
(Real Time Quote from BATS)
$0.55 USD
-0.02 (-3.17%)
Updated Oct 8, 2024 02:38 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Biora Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 1 | 74 | 144 |
Cost Of Goods | 0 | 0 | 0 | 93 | 100 |
Gross Profit | 0 | 0 | 1 | -19 | 43 |
Selling & Adminstrative & Depr. & Amort Expenses | 67 | 62 | 119 | 176 | 184 |
Income After Depreciation & Amortization | -67 | -62 | -118 | -195 | -140 |
Non-Operating Income | -47 | 24 | -61 | -25 | 1 |
Interest Expense | 10 | 11 | 0 | 10 | 9 |
Pretax Income | -124 | -49 | -179 | -230 | -149 |
Income Taxes | 0 | 0 | 0 | -38 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -124 | -49 | -179 | -193 | -148 |
Extras & Discontinued Operations | 0 | 11 | -69 | 0 | 0 |
Net Income (GAAP) | -124 | -38 | -247 | -193 | -148 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -65 | -59 | -115 | -186 | -134 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 3 | 9 | 6 |
Income After Depreciation & Amortization | -67 | -62 | -118 | -195 | -140 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 15.77 | 7.64 | 3.85 | 1.10 | NA |
Diluted EPS Before Non-Recurring Items | -3.74 | -8.56 | -39.25 | -175.25 | NA |
Diluted Net EPS (GAAP) | -7.87 | -5.00 | -64.25 | -175.25 | NA |
Fiscal Year end for Biora Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.32 | 0.54 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.32 | 0.54 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 16.10 | 16.06 | 13.35 | 23.32 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -15.78 | -15.52 | -13.35 | -23.32 |
Non-Operating Income | NA | 22.90 | 14.13 | -0.54 | -47.54 |
Interest Expense | NA | 0.71 | 2.76 | 1.84 | 2.59 |
Pretax Income | NA | 6.40 | -4.14 | -15.73 | -73.45 |
Income Taxes | NA | -0.07 | 0.05 | -0.10 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 6.47 | -4.19 | -15.63 | -73.45 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.22 | 0.00 |
Net Income (GAAP) | NA | 6.47 | -4.19 | -15.41 | -73.45 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 74.22 | 29.30 | 24.81 | 15.03 |
Diluted EPS Before Non-Recurring Items | NA | -0.35 | -0.61 | -0.63 | -0.75 |
Diluted Net EPS (GAAP) | NA | -0.04 | -0.14 | 0.08 | -4.89 |